Comparative Pharmacology
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus TETRACAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus TETRACAINE HYDROCHLORIDE.
LIDOSITE TOPICAL SYSTEM KIT vs TETRACAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses.
Tetracaine hydrochloride is a local anesthetic of the ester type that reversibly blocks nerve conduction by decreasing sodium ion permeability across the neuronal membrane, thereby stabilizing the membrane and preventing the initiation and transmission of nerve impulses.
Apply up to 3 patches topically once daily for up to 12 hours per day. Maximum 3 patches (210 mg lidocaine) per day.
Topical: 0.5-2% solution or ointment applied to affected area up to 4 times daily as needed. Maximum single dose: 20 mL of 2% solution (400 mg). Spinal anesthesia: 0.5% solution, 2-3 mL (10-15 mg) injected intrathecally.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic dysfunction or heart failure
Terminal elimination half-life is approximately 1.5–3 minutes in plasma due to rapid hydrolysis; clinical effect duration is dose-dependent (15–30 minutes for topical anesthesia).
Renal (80-90% as metabolites, <10% unchanged), biliary/fecal (minor, <5%)
Primarily metabolized by plasma pseudocholinesterase; renal excretion of metabolites accounts for >95% of elimination, with <2% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Local Anesthetic
Local Anesthetic